Seeking Alpha

Targacept (TRGT +0.2%) completes enrollment in a Phase 2a study of its schizophrenia treatment...

Targacept (TRGT +0.2%) completes enrollment in a Phase 2a study of its schizophrenia treatment TC-5619 which treats the negative symptoms and cognitive dysfunction of the disease, something TRGT's CEO says is novel among treatment options.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector